PremiumCompany AnnouncementsBioCryst Pharmaceuticals Reports Strong Q1 2025 Growth BioCryst Pharmaceuticals Reports Record Growth and Profitability Strong Growth Prospects for BioCryst’s Orladeyo Drive Buy Rating and Increased Price Target PremiumThe FlyBioCryst reports Q1 EPS 0c, consensus (5c) BCRX Upcoming Earnings Report: What to Expect? ARMOUR, BioCryst, Viking, Builders, Hims: Trending by Analysts PremiumThe FlyBioCryst initiated with an Overweight at Cantor Fitzgerald BioCryst Appoints CEO as Interim CFO Amid Transition BioCryst CEO to serve as interim CFO